HRP970173A2 - Arylamino fused pyridines and pyrimidines - Google Patents

Arylamino fused pyridines and pyrimidines

Info

Publication number
HRP970173A2
HRP970173A2 HR60/039,124A HRP970173A HRP970173A2 HR P970173 A2 HRP970173 A2 HR P970173A2 HR P970173 A HRP970173 A HR P970173A HR P970173 A2 HRP970173 A2 HR P970173A2
Authority
HR
Croatia
Prior art keywords
alkyl
cycloalkyl
occurrence
haloalkyl
cor7
Prior art date
Application number
HR60/039,124A
Other languages
English (en)
Croatian (hr)
Inventor
Richard Eric Olson
Original Assignee
Richard Eric Olson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richard Eric Olson filed Critical Richard Eric Olson
Publication of HRP970173A2 publication Critical patent/HRP970173A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Luminescent Compositions (AREA)
HR60/039,124A 1996-03-27 1997-03-26 Arylamino fused pyridines and pyrimidines HRP970173A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1415796P 1996-03-27 1996-03-27
US64661296A 1996-05-08 1996-05-08
US3053696P 1996-10-31 1996-10-31
US3912497P 1997-02-25 1997-02-25

Publications (1)

Publication Number Publication Date
HRP970173A2 true HRP970173A2 (en) 1999-08-31

Family

ID=27486365

Family Applications (1)

Application Number Title Priority Date Filing Date
HR60/039,124A HRP970173A2 (en) 1996-03-27 1997-03-26 Arylamino fused pyridines and pyrimidines

Country Status (21)

Country Link
US (2) US6107300A (cs)
EP (1) EP0935601A4 (cs)
JP (1) JP2002515032A (cs)
KR (1) KR20000005037A (cs)
CN (1) CN1230184A (cs)
AU (1) AU2545897A (cs)
BR (1) BR9708261A (cs)
CA (1) CA2250241A1 (cs)
CZ (1) CZ304098A3 (cs)
EA (1) EA199800868A1 (cs)
EE (1) EE9800329A (cs)
HR (1) HRP970173A2 (cs)
HU (1) HUP9902340A3 (cs)
IL (1) IL126316A0 (cs)
LV (1) LV12262B (cs)
NO (1) NO984418L (cs)
NZ (1) NZ331874A (cs)
PL (1) PL335258A1 (cs)
SI (1) SI9720026A (cs)
SK (1) SK131798A3 (cs)
WO (1) WO1997035539A2 (cs)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1066147C (zh) 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
SK128799A3 (en) * 1997-03-21 2000-05-16 Du Pont Pharm Co Method of making arylamino triazolopyridines
JP2002510322A (ja) * 1997-07-03 2002-04-02 デュポン ファーマシューティカルズ カンパニー 副腎皮質刺激ホルモン放出ホルモン拮抗剤としてのアリールおよびアリールアミノ置換複素環
US6156898A (en) * 1998-02-26 2000-12-05 Neurogen Corporation Substituted 1,4-dihydro-4-oxonicotinic carboxamides; GABA brain receptor ligands
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
NZ510955A (en) 1998-11-12 2003-01-31 Neurocrine Biosciences Inc Tricyclic nitrogen containing ring system useful as CRF receptor antagonists
DE69908173T2 (de) 1998-11-12 2004-08-19 Neurocrine Biosciences, Inc., San Diego Crf rezeptor-antagonisten und darauf bezogene methoden
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
CN1377356A (zh) 1999-09-30 2002-10-30 纽罗杰有限公司 亚烷基二胺取代的杂环
US20020132819A1 (en) * 1999-12-17 2002-09-19 Metcalf Chester A. Novel purinse
US7115589B2 (en) * 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
US6589952B2 (en) 2000-07-14 2003-07-08 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
EP1361880B1 (en) 2001-02-12 2005-09-28 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
CZ20032481A3 (cs) 2001-03-13 2007-12-27 Bristol-Myers Squibb Pharma Company 4-(2-Butylamino)-2, 7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo[1,5-A]-1, 3, 5-triazin, jeho enantiomery a farmaceuticky prijatelné soli jakoligandy receptoru faktoru uvolnujícího kortikotropin
CN1527710A (zh) 2001-05-14 2004-09-08 ����˹�ж�-����˹˹����ҩƷ��˾ 作为促肾上腺皮质激素释放因子配体的取代的吡嗪酮、吡啶和嘧啶
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US6894045B2 (en) 2001-07-12 2005-05-17 Bristol-Myers Squibb Pharma Company Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
GB0117525D0 (en) 2001-07-19 2001-09-12 Procter & Gamble Solvent welding process
GB0117522D0 (en) 2001-07-19 2001-09-12 Procter & Gamble Solvent welding process
US20030119831A1 (en) 2001-11-20 2003-06-26 Hartz Richard A. 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
US9967633B1 (en) 2001-12-14 2018-05-08 At&T Intellectual Property I, L.P. System and method for utilizing television viewing patterns
WO2003051881A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
WO2005026126A1 (ja) * 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. Crf拮抗剤および二環式複素環化合物
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US20070197559A1 (en) * 2004-03-02 2007-08-23 Rajagopal Bakthavatchalam Aryl substituted purine analogues
EP1598354A1 (en) * 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation
AU2005270068B2 (en) * 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
CA2573538C (en) * 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
US7238702B2 (en) * 2005-02-10 2007-07-03 Bristol-Myers Squibb Company Dihydroquinazolinones as 5HT modulators
EP1703668A1 (en) * 2005-03-18 2006-09-20 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO System for processing quality-of-service parameters in a communication network
DK1904504T3 (da) * 2005-05-20 2014-06-23 Methylgene Inc Inhibitorer af vegf-receptor- og hgf-receptorsignalering
AU2006343808B2 (en) * 2005-05-20 2012-03-29 Mirati Therapeutics, Inc. Inhibitors of VEGF receptor and HGF receptor signaling
ES2441873T3 (es) 2005-05-26 2014-02-06 Aldexa Therapeutics, Inc. Derivados de quinolina para el tratamiento de enfermedades retinianas
CA2617102A1 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
CA2628936A1 (en) * 2005-11-08 2007-05-18 F. Hoffmann-La Roche Ag Thiazolo [4 , 5-c] pyridine derivatives as mglu5 receptor antagonists
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
EP2044086A2 (en) * 2006-06-30 2009-04-08 Janssen Pharmaceutica N.V. Thiazolopyrimidine modulators of trpv1
WO2008054796A2 (en) 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
WO2008054795A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
KR20090101370A (ko) * 2007-01-10 2009-09-25 알바니 몰레큘라 리써치, 인크. 5-피리디논 치환된 인다졸
EP2176251B1 (en) * 2007-07-21 2012-02-08 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles and pharmaceutical compositions thereof
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
AU2009221583B2 (en) * 2008-03-05 2013-06-20 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
AU2010204619B2 (en) 2009-01-16 2016-08-11 Exelixis, Inc. Malate salt of N-(4-{ [ 6, 7-bis (methyloxy)-quinolin-4-yl] oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
CN107709326B (zh) * 2015-02-18 2021-12-17 巴克老龄问题研究所 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶
CA2996183A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11370793B2 (en) 2015-08-27 2022-06-28 Nantneuro, Llc Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US20210130352A1 (en) * 2018-06-21 2021-05-06 Janssen Pharmaceutica Nv Oga inhibitor compounds
WO2020033344A1 (en) * 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN115697336A (zh) 2020-05-13 2023-02-03 奥尔德拉医疗公司 药物制剂及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
US4076711A (en) * 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
EP0155911A1 (de) * 1984-03-19 1985-09-25 Ciba-Geigy Ag Purinderivate zur Regulierung des Pflanzenwachstums
GB8408615D0 (en) * 1984-04-04 1984-05-16 Wellcome Found Heterocyclic compounds
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US5175273A (en) * 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
US5240937A (en) * 1990-04-20 1993-08-31 Burroughs Wellcome Co. Pharmaceutically active triazolopyridine compounds
FI933303L (fi) * 1991-01-23 1993-08-31 Gensia Inc Adenosinkinasinhibitorer
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
DK0619805T3 (da) * 1991-11-25 2000-06-05 Pfizer 5-(Hetero-eller carbocyclylamino)-indolderivater, deres fremstilling og anvendelse som 5-HT1-agonister
DE69324244T2 (de) * 1992-01-06 1999-09-30 The Wellcome Foundation Ltd., Greenford Therapeutische nukleoside der 2',3'-dideoxy-3'-fluor -purin reihe
US5424297A (en) * 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
CA2192208C (en) * 1994-06-06 2002-09-10 Pfizer Limited Substituted pyrazoles
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
PL181895B1 (pl) * 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
DE69603240T2 (de) * 1995-05-12 2000-01-05 Neurogen Corp., Branford Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
DE69628804T2 (de) * 1995-12-08 2003-12-18 Pfizer Inc., New York Substitutierte heterozyclische Derivate als CRF Antagonisten

Also Published As

Publication number Publication date
KR20000005037A (ko) 2000-01-25
EE9800329A (et) 1999-06-15
CA2250241A1 (en) 1997-10-02
IL126316A0 (en) 1999-05-09
NO984418D0 (no) 1998-09-22
WO1997035539A2 (en) 1997-10-02
CZ304098A3 (cs) 1999-02-17
HUP9902340A3 (en) 2001-02-28
WO1997035539A3 (en) 1999-05-14
EP0935601A2 (en) 1999-08-18
LV12262A (lv) 1999-04-20
EA199800868A1 (ru) 1999-04-29
EP0935601A4 (en) 2002-08-07
LV12262B (en) 1999-10-20
US6448261B1 (en) 2002-09-10
PL335258A1 (en) 2000-04-10
JP2002515032A (ja) 2002-05-21
BR9708261A (pt) 2001-12-04
SK131798A3 (en) 2000-05-16
NO984418L (no) 1998-11-03
US6107300A (en) 2000-08-22
SI9720026A (sl) 1999-04-30
AU2545897A (en) 1997-10-17
CN1230184A (zh) 1999-09-29
HUP9902340A2 (hu) 1999-11-29
NZ331874A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
US6448261B1 (en) Arylamino fused pyridines
US6245769B1 (en) Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
US6191131B1 (en) Azolo triazines and pyrimidines
KR100548853B1 (ko) 아졸로 트리아진 및 피리미딘
EP1344779B1 (en) Azolo-pyrimidines
US6136809A (en) Azolo triazines and pyrimidines
WO1999001439A1 (en) Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
JP2000511183A (ja) 神経学的疾患治療のためのテトラヒドロプテリジンおよびピリジルピペラジン
EP1140929B1 (en) 1h-imidazo 4,5-d]pyridazin-7-ones, 3h-imidazo 4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (crf) receptor ligands
US6313124B1 (en) Tetrazine bicyclic compounds
US20020147338A1 (en) Pyrazolotriazines as CRF antagonists
US6630476B2 (en) Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
US6174912B1 (en) Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
JP4194539B2 (ja) アゾロトリアジン類およびアゾロピリミジン類
US20030008885A1 (en) Azolo triazines and pyrimidines
US7094782B1 (en) Azolo triazines and pyrimidines
LT4533B (lt) Kondensuoti arilaminopiridinai ir pirimidinai
MXPA98007759A (en) Pyridines and pyrimidines fused with arilam
HK1060348B (en) Azolo-pyrimidines

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBI Application refused